Actelion selects IntraLinks for clinical trial data exchange

Streamlines documentation process while improving efficiency and security

Swiss biopharmaceutical firm Actelion Pharmaceuticals has selected IntraLinks’ Connect system to streamline its documentation exchange during clinical trials.

Allschwil/Basel-based Actelion focuses on the discovery, development, and commercialisation of medicines to serve unmet medical needs.

IntraLinks is a global technology provider of content management and collaboration solutions.

Actelion had previously relied on traditional courier services to move sensitive clinical trial documentation between sponsors and participants, resulting in excessive shipping costs and manual processes for tracking and other activities.

To streamline the documentation process and improve efficiency and security, Actelion will use IntraLinks Connect to provide central clinical trial portals to facilitate auditable exchange of site feasibility, study start up, study conduct and study close-out documentation.

IntraLinks Connect's security, detailed reporting, workflows, and analytics, plus the firm’s service support convinced Actelion that IntraLinks provided the best fit for its requirements.

Christine Schwenninger, head of Global Clinical Monitoring at Actelion, said: ‘While working with IntraLinks we can see the maturity of their technology and the commitment of the team to support Actelion moving forward in this area.

‘We are looking forward to working closely together with IntraLinks in the coming years.’

Andy Watson, vp of life sciences EMEA at IntraLinks, added: ‘Actelion's engagement of IntraLinks demonstrates the growing demand for secure information exchange within the clinical trial process.’

‘IntraLinks’ Connect will provide Actelion with greater efficiency, traceability, and security to improve communication, collaboration, and document exchange between everyone involved in the clinical trial.’

Companies